Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We read with interest the paper by Zoller et al comparing the rate of hypophosphataemia with ferric carboxymaltose (FCM) versus ferric derisomaltose (FDI) infusions in patients with inflammatory bowel disease (IBD).1 The higher rate of hypophosphataemia following FCM replicates findings of other studies in patients with and without IBD.2 3 Iron deficiency anaemia is associated with reduced quality of life, increased hospitalisation and impairments in physical and cognitive function in patients with IBD,4 and further evidence to support decision making regarding appropriate intravenous iron replacement is welcome.
The effect of FCM on markers of bone turnover, noted by Zoller and colleagues, is of particular concern, especially the persistence of raised bone-specific alkaline phosphatase (ALP) to day 70. Patients with IBD have a higher risk of osteopenia and osteoporosis due to chronic inflammation, steroid use and nutritional deficiencies.5 Given that the …
AC and SL are joint first authors.
Correction notice This article has been corrected since it published Online First. The first authorship statement has been added.
Contributors AC, SL and MG performed literature review, drafted the article and approved the final version.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.